Online inquiry

IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ82MR)

This product GTTS-WQ82MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets H1-0 gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_005318.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3005
UniProt ID P07305
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ82MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15883MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ7793MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GS-HIV
GTTS-WQ3378MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ5514MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ2600MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ5783MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ14044MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ3994MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BG9924
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW